Tirzepatide is a novel dual GLP-1 and glucose-dependent insulinotropic peptide (GIP) receptor agonist, and its therapeutic efficacy in improving NASH has been reported in a clinical trial (Hartman et al., 2020). This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.